Abstract
Regulatory toxicology studies are considered the backbone of pharmaceutical research and drug development. The results of the preclinical data are critical to take decisions during the drug development phase. Every new chemical entity or molecule is hazardous in nature. It is the dose that determines its beneficial effects on living creatures like human beings, rodents, etc., and is expressed as a margin of safety. General toxicology includes toxicity studies on rodents and non-rodents, determination of maximum tolerated doses, dose range findings, acute, subacute, and chronic toxicity, no observable adverse effect levels, etc. The core battery of tests on different systems like the cardiovascular system, central nervous system, respiratory system, etc., are also required to be performed during safety pharmacology. Other tests like genotoxicity and carcinogenicity are also being conducted under ICH guidelines during the drug discovery and development phase. Moreover, most importantly, reproductive toxicology studies have also been made mandatory during the drug development phase. Therefore, this chapter explained the role of toxicology studies in pharmaceutical product development, starting from the basics of toxicology to the regulatory requirements of toxicological studies in pharmaceutical product development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ashton GA, Griffiths SA, McAuslane JAN (1999) Industry experience with alternative models for the carcinogenicity testing of pharmaceuticals. Centre for Medicines Research International, Surrey, U.K.
Baille TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188–196
Bakke OM, Manocchia MA, deAbajo F, Kaitin KI, Lasagna L (1995) Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther 58:108–117
Bass R, Scheibner E (1987) Toxicological evaluation of biotechnology products: a regulatory viewpoint. Arch Toxicol Suppl 11:182–190
Beary JF III (1997) The drug development and approval process. In New drug approvals in 1997. Pharmaceutical Research and Manufacturers of America, Washington, DC
Bolon B (2004) Genetically engineered animals in drug discovery and development: a maturing resource for toxicologic research. Basic Clin Pharmacol Toxicol 95:154–161
Bucher JR, Portier CJ, Goodman JI, Faustman EM, Lucier GW (1996) NationalToxicology program studies: principles of dose selection and applications to mechanistic based risk assessment. Fundam Appl Toxicol 31:1–8
Calabrese EJ, Baldwin LA (1994) Improved method for selection of the NOAEL. Regul Toxicol Pharmacol 19:48–50
Cavagnaro JA (1997) Considerations in the preclinical safety evaluation of biotechnology derived products. In: Sipes IG, McQueen CA, Gandolphi J (eds) Comprehensive toxicology, vol 2: toxicological testing and evaluation. Elsevier Science Publishing, New York, pp 291–298
Centre for Medicines Research International (1998) Safety evaluation of biotechnology-derived pharmaceutical: facilitating a scientific approach. In: Griffiths SA, Lumley CE (eds) CHMP. 2004. Position paper on nonclinical safety studies to support clinical trials with a single microdose. 23 June. CPMP/SWP/2599/02Rev1. Kluwer Academic Publishers, London
Choudary J, Contrera JF, DeFelice A, DeGeorge JJ, Farrelly JG, Fitzgerald G, Goheer MA, Jacobs A, Jordan A, Meyers L, Osterberg R, Resnick C, Sun CJ, Temple RJ (1996) Response to Monro and Mehtaproposal for use of single-dose toxicology studies to support single-dose studies of new drugs in humans. Clin Pharmacol Ther 59:265–267
Clewell HJ, Andersen ME (1986) Dose, species, and route extrapolation using physiologically based pharmacokinetic models. In Pharmacokinetics in risk assessment, drinking
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Abhishek, M., Rubal, S., Rupa, J., Bikash, M. (2023). Toxicology of Pharmaceutical Products During Drug Development. In: Mohanan, P.V., Kappalli, S. (eds) Biomedical Applications and Toxicity of Nanomaterials. Springer, Singapore. https://doi.org/10.1007/978-981-19-7834-0_7
Download citation
DOI: https://doi.org/10.1007/978-981-19-7834-0_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-7833-3
Online ISBN: 978-981-19-7834-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)